Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ligand-gated Ion Channels

Ligand-gated Ion Channels

Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that include the...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Royal College of Physicians of Edinburgh stands against the wood burning lobby.

BMJ (Clinical research ed.)·2026

Same author

Proximity of city schools in Scotland to air quality monitors: an exploratory geomapping study in five Scottish cities.

BMJ public health·2026

Same author

Treatment Guidelines and Decision Tree for Dry Needling Musculoskeletal Conditions: A Consensus Statement.

International journal of sports physical therapy·2026

Same author

Clinical and genetic correlates of a circadian subtype of depression in the Australian Genetics of Depression Study.

medRxiv : the preprint server for health sciences·2026

Same author

Protocol for enhancing CRISPR-Cas9 genome editing using histone deacetylase inhibition and engineered virus-like particle delivery.

STAR protocols·2026

Same author

One Eye Open: Reflections on Embedding Lived Experience in Sleep, Circadian Rhythms, and Mood Disorder Research.

Health expectations : an international journal of public participation in health care and health policy·2026

Search research articles

Related Experiment Video

Updated: Jul 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Allopurinol improves endothelial dysfunction in chronic heart failure.

Colin A J Farquharson¹, Robert Butler, Alexander Hill

¹Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK.

|July 10, 2002

Summary

Allopurinol significantly improved endothelial dysfunction in patients with chronic heart failure by reducing oxidative stress. This suggests potential benefits for cardiovascular events and exercise capacity.

Related Experiment Videos

Last Updated: Jul 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Area of Science:

Cardiology
Pharmacology
Oxidative Stress Research

Background:

Oxidative stress is implicated in endothelial dysfunction in chronic heart failure.
Xanthine oxidase is a key enzyme producing oxidative stress.

Purpose of the Study:

To investigate the effect of allopurinol on endothelial dysfunction in chronic heart failure.
To determine if allopurinol reduces oxidative stress markers in these patients.

Main Methods:

A randomized, placebo-controlled, double-blind crossover study involving 11 patients with chronic heart failure (New York Heart Association class II-III).
Patients received either 300 mg allopurinol daily or placebo for one month.
Endothelial function was assessed using forearm venous occlusion plethysmography with acetylcholine, nitroprusside, and verapamil.
Plasma malondialdehyde levels were measured as a marker of oxidative stress.

Main Results:

Allopurinol significantly enhanced the forearm blood flow response to acetylcholine compared to placebo (181+/-19% vs. 120+/-22%, P=0.003).
No significant differences were observed in responses to nitroprusside or verapamil between treatment groups.
Allopurinol treatment led to a significant reduction in plasma malondialdehyde levels (346+/-128 nmol/L vs. 461+/-101 nmol/L, P=0.03), indicating reduced oxidative stress.

Conclusions:

Allopurinol effectively improves endothelial dysfunction in patients with chronic heart failure.
These findings suggest that allopurinol may offer a therapeutic benefit in reducing cardiovascular events and enhancing exercise capacity in this patient population.